InvestorsHub Logo
Boards
News
Market Data
Markets
Discover
Discover
Subscribe Login/Register
S&P 500
5,214.08
(
0.51%
)
US TECH 100
17,660.00
(
0.33%
)
Dow Jones
39,387.76
(
0.85%
)
Brent Oil
84.15
(
0.23%
)
Bitcoin
62,879.54
(
-0.27%
)
Post# of 3331
Next 10
Reply Private New
Public Reply Private Reply New Post
Keep Last Read
Keep Next 10 Report Keyboard Shortcuts
Next 10 Prev Next

ash111

Send PM Follow Ignore
Followers 1055
Posts 189434
Boards Moderated 1
Alias Born 06/19/2009

ash111

Re: ash111 post# 1618

Friday, 10/12/2018 9:43:36 AM

Friday, October 12, 2018 9:43:36 AM

Post# of 3331
$ZYNE
Major Catalysts ahead ( Q4). new Presentation on Board. Consensus P.T By 5 Analysts is around $21
One of the many drugs in its pipeline is ZYN002, the only cannabidiol gel currently undergoing FDA trials — it has three Phase II studies underway.fully Funded.

Arlinda Lee,PhD
Success Rate on Stock 50%
https://t.co/9M96hzxwPX
"ZYN002 could provide the basis for regulatory approval"..

Gets Buy Rating, $25.50 Target Price From Ladenburg Thalman
Higgins also thinks that Zynerba has an advantage over GW Pharmaceuticals’ Epidiolex drug.
https://www.greenmarketreport.com/zynerba-gets-buy-rating-25-50-target-price-ladenburg-thalman/

$ZYNE analyst number 3.
CANTOR FITZGERALD
We rate 12-month PT of $20/share. Zynerba is developing ZYN002, a synthetic CBD gel to treat neurological conditions. 
https://t.co/Tv0javh00T https://t.co/EHAqaPzXIl



My posts are my opinion and should not be used as investment advice. Make your own decisions in your stock trades.

Public Reply Private Reply New Post
Keep Last Read
Keep Last Read Next 10 Report Keyboard Shortcuts
Next 10 Prev Next

Join the InvestorsHub Community

Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.

Sign Up